Envoy Medical Announces Publication of Additional Patent for Implantable Cochlear Systems

Newly Published Patent Contemplates an Evolving Product Portfolio to Serve the Under-Penetrated Hearing Implant Market

WHITE BEAR LAKE, Minnesota, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Envoy Medical, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it has been awarded another patent. This patent – “Implantable Cochlear System with Inner Ear Sensor” (Document ID: US 11806531 B2) – is one of a growing number of patents that Envoy Medical has applied for or secured as part of its implantable hearing devices technology portfolio.

“We are excited to announce this new patent, which gives us an additional opportunity to evolve and grow our designs over time. We’ve made no secret of our intent to disrupt the hearing implant market with our fully implanted Acclaim cochlear implant, but we also have a strategy to maintain that momentum with additional advances in the implantable hearing device market for years to come,” said Brent Lucas, Envoy Medical’s Chief Executive Officer.

About Envoy Medical

Envoy Medical, Inc. (NASDAQ: COCH), headquartered in White Bear Lake, Minnesota, is a hearing health company focused on providing innovative medical technologies.

Envoy Medical is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.

About the Fully Implanted Acclaim Cochlear Implant

We believe the fully implanted Acclaim Cochlear Implant will be a first-of-its-kind fully implanted cochlear implant. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

The Acclaim is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. We believe the Acclaim was the first hearing-focused device to receive Breakthrough Device Designation.

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by United States law to investigational use.

Important safety information for the Esteem can be found at: https://www.envoymedical.com/safety-information.